Lifecycle & sector classification. FMP tags the industry "Biotechnology," but on the metrics that matter VRTX is a Mature Healthcare/Pharma name, not a pre-revenue clinical biotech: it is solidly profitable ($4.34B TTM net income), generates ~$3.7B free cash flow, carries net cash, and grows revenue ~8% YoY. We score it on mature-pharma metrics (margins, ROE/ROIC, FCF, R&D efficiency, patent-cliff exposure) — not the pre-revenue cash-runway/phase lens.
| Sub-signal | Value | Sector norm | Score | Read |
|---|---|---|---|---|
| Revenue trajectory | +7.8% YoY (Q1'26); TTM $12.26B | >5% strong for pharma | 72 | Steady high-single-digit growth; consensus +8.8% '26, +9.5% '27 |
| Profitability vs peers | Op 39.0% · Net 35.4% · Gross 86.3% | Large-pharma op ~30% | 92 | Top-decile margins; orphan-drug economics |
| Cash generation | FCF margin ~30%; FCF/OCF conv 87% | Quality pharma 20-30% | 85 | Cash-rich; ~$3.7B FCF, $14.60 FCF/sh |
| Balance-sheet health | Net cash; D/E 0.10; cur 3.0x; int cov 463x | Net debt/EBITDA <2x healthy | 95 | Fortress balance sheet — ~$7.2B cash |
| R&D efficiency / pipeline | R&D ~$3.9B/yr; 5 approved + Ph3 pipeline | Deep pipeline + low cliff | 80 | Casgevy, Journavx, Alyftrek; inaxaplin Ph3, zimislecel |
Moat average 74/100. Switching-cost and cost-advantage sub-scores are derived from the Competitive Environment read below, not asserted.
The CF franchise is effectively a monopoly — rivals abandoned the field — so the core moat is intact and stable. The competitive pressure is on the new growth franchises VRTX is using to diversify (non-opioid pain, gene therapy, diabetes), which is why the moat earns "stable," not "gaining," and why threat level is moderate rather than low.
| Competitor | Threat type | Share trajectory | Moat-erosion vector |
|---|---|---|---|
| AbbVie / Galapagos (CF) | Direct merchant rival | VRTX dominant / gaining | Rivals exited CF; near-zero erosion of the core |
| Eli Lilly (LLY) — pain | Direct merchant rival | VRTX early leader, watch share | Per 20 Jun 2026 reporting, Lilly is spending billions to enter non-opioid pain — caps Journavx's runway |
| Other NaV1.8 / pain players | Disruptive entrants | Stable, contested | Class competition could pressure Journavx pricing/share long-term |
| bluebird bio (Lyfgenia) etc. | Substitute (gene therapy) | Stable, contested | Competes with Casgevy in sickle-cell; both face slow ex-vivo uptake |
| Generics (older CF drugs) | Low-cost entrant | Minor near-term | Kalydeco/older agents face eventual generic exposure; small revenue share |
→ Net effect on the moat: Switching Costs held at 80 and Cost Advantage at 62 — the CF lock-in is not decaying, but the new franchises face credible rivals (most notably Lilly in pain), so we do not award expansion credit. competitive_threat_level = moderate; share_trajectory = stable. This propagates to the §11 Bear trigger (pain/gene-therapy competition + CF concentration) and the §12 thesis-invalidation rule.
| Dimension | Read | Score |
|---|---|---|
| ROIC vs peers | ~20%+ on low invested capital; ROE 22.4%, ROA top-tier (FMP ROE/ROA both 5/5). Top-quartile, stable. | 82 |
| Capital-allocation discipline | Disciplined tuck-in M&A (Alpine→inaxaplin, Semma→diabetes); buybacks; no dividend — reinvests at high ROIC. | 78 |
| Management skin-in-the-game | CEO R. Kewalramani well-regarded; moderate SBC (not a dilution flag); net buybacks. | 72 |
Quality verdict: 86/100 (High). One of the highest-quality businesses in healthcare — elite margins, fortress balance sheet, durable CF monopoly. The single caveat is franchise concentration, captured in the driver and the bear case rather than the quality number.
| Lens | Reading | Score | Interpretation |
|---|---|---|---|
| Sector median multiple (25%) | Fwd P/E ~23.4x vs big-pharma mid-teens / quality-growth biotech 25-30x+ | 42 | Premium to big pharma, in-line to cheap vs growth peers |
| Own 5-yr historical decile (20%) | TTM P/E 26.5 sits mid-range of its own 20-30x band | 55 | Neither washed out nor extreme — ~5th decile |
| Growth-adjusted PEG (15%) | Fwd P/E 23.4 ÷ ~12% EPS CAGR → PEG ~1.9 (FMP fwd PEG 2.2) | 45 | Full but not egregious for the quality |
| Reverse-DCF implied growth (25%) | Gordon shortcut (FCF yield ~3.4% vs ~8% WACC) implies only ~5-6% perpetual growth vs ~12% consensus | 72 | Market prices in LESS growth than analysts — pessimistic (simplified lens, directional) |
| Analyst target + grades (15%) | Price $451.63 vs consensus $553.93 / median $558 (+22.6%/+23.5%); high $616, low $436. 47 Buy / 9 Hold / 0 Sell (84% bullish) | 83 | >20% below consensus — strong target support |
Note (2026-07-03 anchor): these five lenses are now context, not the score. The pillar score is set by the warranted-multiple anchor below (actual ÷ warranted, subject to the per-sector guardrail floor); the lenses inform the narrative and the confidence, not the number.
The ~23x forward multiple is supported by the CF cash machine; several pipeline assets are valued at close to zero in that price:
Framing: the in-production CF + early-launch business justifies roughly the current ~$450; the kidney/diabetes options are largely free at this price. This is a tilt (+~5), not a re-rating — it is the reason to keep watching, not proof the stock is cheap.
Valuation is now scored as actual ÷ warranted multiple, where the warranted multiple is a two-stage DCF off a disciplined discount rate and growth cap, subject to a per-sector guardrail floor:
→ High Quality (86) + Expensive → HOLD; STRONG-BUY amplification blocked.
Valuation verdict: 37/100 (Expensive). On the new warranted-multiple anchor the clean 29.5× P/E sits above both its ~23× warranted multiple (ratio 1.28) and — decisively — the 22× Health-Care guardrail floor, which is the binding constraint. The reverse-DCF/consensus-gap read still argues the market is not paying up for the pipeline, but that is now a watch item, not enough to override a clean multiple above the sector guardrail. Earnings-quality check (step 7b): clean (operating-only) P/E ~29.5 vs reported 26.5 — interest income is ~11% of net income; the clean multiple is what the guardrail is measured against. Net: Expensive → HOLD.
For a single-franchise pharma, the dominant external force is the durability of the lead franchise versus the maturation of the pipeline that diversifies away from it — overlaid with drug-pricing policy (IRA/Medicare negotiation). This is what sits above VRTX's own execution.
| Horizon | Read | Weight |
|---|---|---|
| Historical (25%) | CF revenue compounded steadily; franchise broadened (Kalydeco→Orkambi→Trikafta→Alyftrek); Casgevy & Journavx added new modalities. 70 | 25% |
| Current (50%) | Trikafta/Alyftrek dominant and growing; Journavx + Casgevy launching; net cash funds pipeline. Offsets: ~90% revenue concentration in CF and a persistent drug-pricing-policy overhang. 68 | 50% |
| Forward (25%) | Pipeline maturing into large TAMs — inaxaplin Ph3 (APOL1 kidney), zimislecel (T1 diabetes), Journavx label expansion; vanza triple extends CF IP toward ~2037. 70 | 25% |
Driver score: 68/100 — Tailwind. At ≥65 the driver is eligible to amplify a BUY to STRONG BUY — but amplification also requires the economy's pressure to be a Tailwind. Here Economic Alignment is Neutral (§6), so no amplification fires — and in any case the Expensive valuation independently blocks STRONG-BUY amplification. The base signal is HOLD on all three horizons (High Quality + Expensive → HOLD). The driver does not change the fundamental pillar scores.
Thesis-invalidation floor: the case breaks if the CF franchise is disrupted (efficacy/safety setback or unexpected competition) and the diversifying pipeline (kidney/pain/diabetes) stalls — concentration is the structural vulnerability. Driver confidence 65% (indirect policy element; pipeline timing uncertainty).
The 2026-06-20 MacroDriver report rates Health Care (XLV) Short Underperform, Medium Neutral, Long Outperform under a 'Soft Landing / Reacceleration co-lead (hawkish Fed, higher-for-longer)' regime. Anchoring pressure on the Medium horizon gives Neutral — so the amplification layer is not triggered on any horizon (a Neutral economy enables neither STRONG BUY nor STRONG SELL). Note the divergence: the sector is a mild near-term headwind (rotation toward cyclicals/financials) but a long-term tailwind (defensive demand, rate relief later). VRTX's low beta (0.31) makes it a classic defensive that lags risk-on tapes and outperforms in stress. Net: macro is informational, not a material swing factor — conviction 52, and it does not change the base signal, which is HOLD on all horizons (set by the Expensive valuation, not by macro).
Source: sector-map (GICS Health Care → XLV); VRTX not a named macro-watchlist stock · Macro report 2026-06-20
| Sub-signal | Reading | Score |
|---|---|---|
| MTF trend (30%) | Monthly/Weekly/Daily all uptrend; daily MACD histogram positive & rising 4+ sessions; RSI 56; price > SMA50 ($438) & SMA200 ($439.6). 15-min weakening. Confluence: strongly bullish. | 76 |
| Risk-reward (20%) | Stop below daily swing ($412) is ~9% / ~3.4 ATR away — a wide stop; price mid-upper of 52-wk range (~61%). Not at a support entry. | 50 |
| Macro overlay (10%, low-sens sector) | XLV short = underperform; Fed higher-for-longer; defensive beta 0.31 lags risk-on. Neutral-to-soft. | 50 |
| Sentiment (20%) | 1 upgrade (Maxim, Mar), 0 downgrades in 30d, rest maintains; positive pipeline news flow (kidney, non-opioid pain leadership). A 'death cross' (50d under 200d) is flashing but Street is openly ignoring it. | 62 |
| Catalyst (20%) | No earnings within 30 days (next ~early Aug); pipeline readouts ongoing but no dated binary in the window — calm calendar. | 78 |
Relative strength: as a low-beta defensive, VRTX has lagged the broad tape during the risk-on rotation (consistent with XLV short-underperform) but is holding its own uptrend — a leader within a lagging sector. (No live SPY/sector-ETF return feed this run; RS read is qualitative.)
Honest read on the tape: the bullish structure is real, but the 18 Jun session that printed 2.14× average volume was a −1.6% down day (from $458.99 to $451.63) — distribution, not a breakout-confirming up-day. The trend deserves the 76 on structure; we do not credit a "high-volume breakout." Net Timing 65 (Improving) — good enough to support a BUY, not a chase.
| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| 2026-06-23 | S&P Global Composite/Services PMI (Jun) | Medium | 50.8 / 51.0 | 51.5 / 50.7 | ⚠ Low | Healthcare is low macro-sensitivity; growth-stock valuation read-through only |
| 2026-06-24 | New Home Sales (May) | Medium | 2.9% | -6.2% | ⚠ Low | Not relevant to VRTX directly |
| ~2026-08 (est) | VRTX Q2 2026 earnings | High | — | — | ✅ Yes | Company-specific catalyst — drives the next scheduled update; outside this 14-day window |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-06-17 | FOMC decision + projections | — | Hawkish hold | Hold | Higher-for-longer; mild pressure on long-duration growth valuations |
| 2026-06-18 | Philadelphia Fed Mfg (Jun) | 10.3 | 10.0 | +3% (above) | Risk-on signal — favours cyclicals over defensives like VRTX short-term |
Healthcare/Pharma is a low macro-sensitivity sector, so the §8 high-sensitivity WAIT-override does not apply to VRTX. No high-impact, VRTX-relevant macro release sits inside the next 14 days. The only material dated catalyst is Q2 earnings (~early August), which is what sets the next-update cadence. The post-FOMC, risk-on tape is a mild near-term headwind for a defensive name — consistent with XLV short = underperform — but it is a positioning headwind, not a fundamental one.
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend | Bullish | 52.9 | +, hist easing | S: $391 / R: $508 | Resist. breakout | 0.6x |
| Weekly | Uptrend | Bullish | 52.6 | flat (~0) | S: $403 / R: $508 | Resist. breakout | 1.2x |
| Daily | Uptrend | Bullish | 56.0 | +, rising | S: $412 / R: $457 | Resist. breakout | 2.1x (down day) |
| Hourly | Strong uptrend | Bullish | 49.1 | -, softening | S: $440 / R: $465 | — | n/a |
| 15-min | Weakening | Bearish | 48.1 | - | S: $450 / R: $465 | Support breakdown | n/a |
| Confluence: Strongly bullish (higher TFs aligned; intraday cooling) · MTF Score 76 | |||||||
Monthly, weekly and daily all read uptrend with price above a rising SMA50 ($438) and SMA200 ($439.6), and the daily MACD histogram has been positive and rising for several sessions — a textbook intact uptrend. The only caution flags are intraday (15-min weakening) and the fact that the highest-volume recent session (18 Jun, 2.1×) was a down day, i.e. some distribution into the move. A 'death cross' on the daily (50d marginally below 200d) is technically present but the price is above both averages and the cross is being driven by the spring base, not fresh weakness. Key levels: support $412 (daily swing) then $362 (52-wk low); resistance $457 then the $508 52-wk high.
6-month daily close (18 Dec 2025 – 17 Jun 2026) with SMA50 (orange). Price reclaimed the $438 SMA50 in mid-June and holds the primary uptrend; $412 is the first support, $508 the 52-week high. The March $508 spike marked the high; the stock based around $425-$450 since.
Journavx scales in acute pain and expands toward chronic; inaxaplin Ph3 hits in APOL1 kidney; Casgevy uptake accelerates; multiple re-rates toward the $616 Street high as the franchise visibly diversifies beyond CF. Net-cash optionality funds further tuck-ins.
CF franchise (Trikafta/Alyftrek) keeps compounding ~8-10%; Journavx and Casgevy ramp steadily; pipeline de-risks on schedule. Price converges to the ~$558 analyst median over 12 months as ~12% EPS growth is delivered.
Competitive trigger: Eli Lilly's entry into non-opioid pain compresses Journavx's runway and pricing, and/or a CF-franchise setback exposes the ~90% concentration; a pipeline miss (kidney/diabetes) removes the diversification story. Drug-pricing policy (IRA) bites. Multiple de-rates toward the low-$380s / $362 52-wk low.
Probability-weighted 12-month fair value ≈ $530 (0.25×625 + 0.50×558 + 0.25×380), ~+17% from $451.63 — a favourably skewed payoff anchored by an elite, cash-generative core, with the bear case driven by competition (Lilly in pain) and CF concentration.
Forecast: The Technical path (intact multi-TF uptrend) still holds, but the Fundamental value path is now broken by the warranted-multiple re-rate — the stock is Expensive (29.5× vs 22× guardrail), so the signal is capped at HOLD and entry conviction is Wait: we do not chase a single technical path into a guardrail-expensive multiple. The Catalyst group is event-dependent (Q2 earnings ~early August 2026: >+5% up-move + raised guidance on >2× volume — FORECAST possible, CONFIDENCE Moderate). A pullback toward the ~23× warranted / 22× guardrail zone (roughly the low-$350s on current clean EPS) would reopen the Fundamental value path and move conviction off Wait.
Forecast: Stop is ~10% below price and below both the 50- and 200-day averages — FORECAST: unlikely in the next 4-6 weeks barring a market-wide selloff or a CF/pain competitive shock. Profit-trim trigger ($558 + RSI>70) is ~24% away — not in view near-term. Thesis-invalidation is the one to monitor: track Lilly's pain program and CF revenue concentration at Q2.
Position sizing not computed — specify your portfolio allocation and role for sizing guidance.
{
"ticker": "VRTX",
"exchange": "NASDAQ",
"exchange_ticker": "NASDAQ:VRTX",
"isin": "US92532F1003",
"api_ticker": "VRTX",
"date": "2026-06-20",
"version": "v6",
"analysis_status": "on-going",
"finder_ticker": "VRTX",
"finder_exchange": "NASDAQ",
"finder_fit": 74,
"company": "Vertex Pharmaceuticals Incorporated",
"sector": "Health Care",
"lifecycle_stage": "mature",
"user_horizon": null,
"user_allocation_pct": null,
"portfolio_role": null,
"price_at_rating": 451.63,
"signal_short": "HOLD",
"signal_medium": "HOLD",
"signal_long": "HOLD",
"primary_signal": "HOLD",
"quality_score": 86,
"valuation_score": 37,
"timing_score": 65,
"driver_score": 68,
"economic_alignment_conviction": 52,
"overall_confidence": 70,
"quality_detail": {
"industry_benchmark_name": "R&D Efficiency + Patent-Cliff Exposure",
"industry_benchmark_value": "low near-term cliff; ~90% CF concentration",
"industry_benchmark_score": 80,
"moat_score": 74,
"roic_percentile_vs_peers": 82,
"capital_allocation": 78,
"management_skin_in_game": 72
},
"valuation_detail": {
"fcf_yield": 3.4,
"implied_growth_rate": 5.5,
"consensus_growth_rate": 12.0,
"historical_valuation_decile": 5,
"forward_pe": 23.4,
"trailing_pe": 26.5
},
"timing_detail": {
"mtf_confluence": 76,
"risk_reward_score": 50,
"relative_strength_vs_spy": null,
"relative_strength_vs_sector": null,
"catalyst_clustering_score": 78,
"dynamic_macro_weight": 0.1
},
"nonop_pct_of_net_income": 11,
"clean_pe": 29.5,
"clean_peg": 2.4,
"warranted_multiple": 23,
"actual_multiple": 29.5,
"val_multiple_basis": "clean P/E",
"discount_rate_r": 9.0,
"risk_free_10y": 4.48,
"g_near": 10,
"g_term": 3,
"warranted_ratio": 1.28,
"val_band": "expensive",
"competitive_share_trajectory": "stable",
"competitive_threat_level": "moderate",
"economic_alignment_stance": "Neutral",
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-06-20",
"analyst_consensus_target": 553.93,
"analyst_target_high": 616,
"analyst_target_low": 436,
"analyst_target_median": 558,
"analyst_target_upside_pct": 22.6,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 83.9,
"analyst_coverage_count": 56,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"fmp_rating": "A-",
"fmp_overall_score": 4,
"fair_value_est": 530,
"stop_loss": 405,
"target_price": 558,
"scenario_base_target": 558,
"scenario_bull_target": 625,
"entry_groups_met": 1,
"entry_conviction": "Wait",
"exit_groups_live": 0,
"exit_action": "Hold",
"hard_gate_state": "caution",
"gates_triggered": [],
"gates_caution": ["Valuation Ceiling"],
"do_not_buy_triggers": [],
"next_update_date": "2026-07-06",
"next_update_basis": "default +14d (no impactful event in window; next earnings ~early Aug 2026), rolled to trading day",
"next_check_date": "2026-07-06"
}
First report for VRTX — promoted from Stock-Finder (Fit 74). Re-rated 2026-07-03 on the new warranted-multiple valuation anchor: HOLD / HOLD / HOLD at $451.63, Quality 86 / Valuation 37 (was 60) / Timing 65 / Drivers 68 / Economic-Alignment 52, hard-gate CAUTION (Valuation Ceiling), entry conviction Wait. Warranted P/E ~23× (r 9% / g 10%) vs actual clean 29.5× (ratio 1.28), but 29.5× is above the 22× Health-Care guardrail floor → Expensive on the floor. Only the Valuation pillar and its cascades changed this run.